Strongyloides—An uncommon cause of eosinophilia whilst on durvalumab
Abstract Background In malignancy, eosinophils have been shown to play an important role in the tumour micro‐environment. Increasingly, development of eosinophilia with immune checkpoint inhibitor (ICI) use is thought to be predictive of prognosis and development of immune‐related adverse events. Ho...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1682 |